Clinical Trials Logo

Myeloproliferative Disorders clinical trials

View clinical trials related to Myeloproliferative Disorders.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05282719 Enrolling by invitation - Clinical trials for Myelodysplastic/Myeloproliferative Neoplasms

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Start date: April 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy of venetoclax combined with azacytidine in Myelodysplastic / myeloproliferative neoplasms(MDS/MPN), so as to improve the overall survival and treatment status of MDS/MPN patients.

NCT ID: NCT04994158 Enrolling by invitation - Clinical trials for Myeloproliferative Neoplasm

MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis

MASCOT-R
Start date: September 1, 2019
Phase:
Study type: Observational [Patient Registry]

A registry of UK patients diagnosed to have splanchnic vein thrombosis and myeloproliferative neoplasm, including isolated mutation of JAK2V617f. The purpose of the registry is to understand outcomes, treatment variations and data to inform and enable future clinical trial design and facilitate regulatory approval decision-making.

NCT ID: NCT04024761 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Start date: August 31, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT) or HLA matched stem cells. This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years of age or older) with AML, MDS, JMML who relapse after stem cell transplantation using HLA-matched related donor or related donor haploidentical stem cells.

NCT ID: NCT01728402 Enrolling by invitation - Clinical trials for Myelodysplastic Syndromes

Pathogenesis of Hematologic Malignancies

Start date: September 2008
Phase:
Study type: Observational

The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.